Cell Cycle Regulatory Functions of the Human Oncoprotein MDM2

Molecular Cancer Research

Volumn 1, Issue 14, 2003, Pages 1009-1016

  Deb, Swati Palit ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH INHIBITOR; ONCOPROTEIN; PROTEIN MDM2; PROTEIN P14; PROTEIN P19; PROTEIN P53; UBIQUITIN PROTEIN LIGASE; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

BREAST DEVELOPMENT; BREAST EPITHELIUM; BREAST TUMOR; CANCER CELL; CARCINOGENESIS; CARCINOGENIC ACTIVITY; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL LINE; EPITHELIUM CELL; FUNCTIONAL ASSESSMENT; GENE; GENE AMPLIFICATION; GENE LOCUS; GENE MUTATION; GENETIC CODE; GROWTH INHIBITION; GROWTH REGULATION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MAMMARY GLAND; MOUSE DOUBLE MINUTE 2 GENE; NONHUMAN; POLYPLOIDY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REGULATORY MECHANISM; REVIEW; SENSITIVITY ANALYSIS; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY; SOFT TISSUE SARCOMA; TRANSGENIC MOUSE; TUMOR SUPPRESSOR GENE;

ANIMALS; CELL CYCLE; HUMANS; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2;

MURINAE; MUS MUSCULUS;

EID: 0345824732     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (100)

1. Levine, A. J. p53, the cellular gatekeeper for growth and division. Cell, 88: 323-331, 1997.
2. Vogelstein, B. and Kinzler, K. W. The multistep nature of cancer. Trends Genet., 9: 138-141, 1993.
3. Lane, D. P. Cancer. p53, guardian of the genome. Nature, 358: 15-16, 1992.
4. Deb, S. P. Function and dysfunction of the human oncoprotein mdm2. Front. Biosci., 7: d235-d243, 2002.
5. Juven-Gershon, T. and Oren, M. Mdm2: the ups and downs. Mol. Med., 5: 71-83, 1999.
6. Lozano, G. and de Oca Luna, R. M. MDM2 function. Biochim. Biophys. Acta, 1377: M55-M59, 1998.
7. Meltzer, P. S. MDM2 and p53: a question of balance. J. Natl. Cancer Inst., 86: 1265-1266, 1994.
8. Momand, J. and Zambetti G. P. Mdm-2: "big brother" of p53. J. Cell. Biochem., 64: 343-352, 1997.
9. Piette, J., Neel, H., and Marechal V. Mdm2: keeping p53 under control. Oncogene, 15: 1001-1010, 1997.
10. Prives, C. Signaling to p53: breaking the MDM2-p53 circuit. Cell, 95: 5-8, 1998.
11. Fakharzadeh, S. S., Trusko, S. P., and George, D. L. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J., 10: 1565-1569, 1991.
12. Finlay, C. A. The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol. Cell. Biol., 13: 301-306, 1993.
13. Baunoch, D., Watkins, L., Tewari, A., Reece, M., Adams, L., Stack, R., Brown, A., Jones, L., Christian, D., Latif, N., Lawerence, W., and Lane, M. MDM2 overexpression in benign and malignant lesions of the human breast. Int. J. Oncol., 8: 895-899, 1996.
14. Martin, K. J., Graner, E., Li, Y., Price, L. M., Kritzman, B. M., Fournier, M. V., Rhei, E., and Pardee, A. B. Proc. Natl. Acad. Sci. USA, 98: 2646-2651, 2001.
15. Gudas, J., Nguyen, H., Klein, R., Katayose, D., Seth, P., and Cowan, K. Differential expression of multiple MDM2 messenger RNAs and proteins in normal and tumorigenic breast epithelial cells. Clin. Cancer Res., 1: 71-80, 1995.
16. Marchetti, A., Buttitta, F., Girlando, S., Dalla Palma, P., Pellegrini, S., Fina, P., Doglioni, C., Bevilacqua, G., and Barbareschi M. Mdm2 gene alterations and mdm2 protein expression in breast carcinomas. J. Pathol., 175: 31-38, 1995.
17. McCann, A. H., Kirley, A., Carney, D. N., Corbally, N., Magee, H. M., Keating, G., and Dervan, P. A. Amplification of the MDM2 gene in human breast cancer and its association with MDM2 and p53 protein status. Br. J. Cancer, 71: 981-985, 1995.
18. Sheikh, M. S., Shao, Z. M., Hussain, A., and Fontana, J. A. The p53-binding protein MDM2 gene is differentially expressed in human breast carcinoma. Cancer Res., 53: 3226-3228, 1993.
19. Cordon-Cardo, C., Latres, E., Drobnjak, M., Oliva, M. R., Pollack, D., Woodruff, J. M., Marechal, V., Chen, J., Brennan, M. F., and Levine, A. J. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res., 54: 794-799, 1994.
20. Corvi, R., Savelyeva, L., Breit, S., Wenzel, A., Handgretinger, R., Barak, J., Oren, M., Amler, L., and Schwab, M. Non-syntenic amplification of MDM2 and MYCN in human neuroblastoma. Oncogene, 10: 1081-1086, 1995.
21. Florenes, V. A., Maelandsmo, G. M., Forus, A., Andreassen, A., Myklebost, O., and Fodstad, O. MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status. J. Natl. Cancer Inst., 86: 1297-1302, 1994.
22. Habuchi, T., Kinoshita, H., Yamada, H., Kakehi, Y., Ogawa, O., Wu, W. J., Takahashi, R., Sugiyama, T., and Yoshida, O. Oncogene amplification in urothelial cancers with p53 gene mutation or MDM2 amplification. J. Natl. Cancer Inst., 86: 1331-1335, 1994.
23. Ladanyi, M., Cha, C., Lewis, R., Jhanwar, S. C., Huvos, A. G., and Healey, J. H. MDM2 gene amplification in metastatic osteosarcoma. Cancer Res., 53: 16-18, 1993.
24. Ladanyi, M., Lewis, R., Jhanwar, S. C., Gerald, W., Huvos, A. G., and Healey, J. H. MDM2 and CDK4 gene amplification in Ewing's sarcoma. J. Pathol., 175: 211-217, 1995.
25. Landers, J. E., Haines, D. S., Strauss, J. F., 3rd, and George, D. L. Enhanced translation: a novel mechanism of mdm2 oncogene overexpression identified in human tumor cells. Oncogene, 9: 2745-2750, 1994.
26. Leach, F. S., Tokino, T., Meltzer, P., Burrell, M., Oliner, J. D., Smith, S., Hill, D. E., Sidransky, D., Kinzler, K. W., and Vogelstein, B. p53 mutation and Mdm2 amplification in human soft tissue sarcomas. Cancer Res., 53: 2231-2234, 1993.
27. Lianes, P., Orlow, I., Zhang, Z. F., Oliva, M. R., Sarkis, A. S., Reuter, V. E., and Cordon-Cardo, C. Altered patterns of MDM2 and TP53 expression in human bladder cancer [see comments]. J. Natl. Cancer Inst., 86: 1325-1330, 1994.
28. Dellas, A., Schultheiss, E., Almendral, A. C., Gudat, F., Oberholzer, M., Feichter, G., Moch, H., and Torhorst, J. Altered expression of mdm-2 and its association with p53 protein status, tumor-cell-proliferation rate and prognosis in cervical neoplasia. Int. J. Cancer, 74: 421-425, 1997.
29. Haidar, M. A., El-Hajj, H., Bueso-Ramos, C. E., Manshouri, T., Glassman, A., Keating, M. J., and Albitar, M. Expression profile of MDM-2 proteins in chronic lymphocytic leukemia and their clinical relevance. Am. J. Hematol., 54: 189-195, 1997.
30. Higashiyama, M., Doi, O., Kodama, K., Yokouchi, H., Kasugai, T., Ishiguro, S., Takami, K., Nakayama, T., and Nishisho, I. MDM2 gene amplification and expression in non-small-cell lung cancer: immunohistochemical expression of its protein is a favourable prognostic marker in patients without p53 protein accumulation. Br. J. Cancer, 75: 1302-1308, 1997.
31. Tanner, B., Hengstler, J. G., Laubscher, S., Meinert, R., Oesch, F., Weikel, W., Knapstein, P. G., and Becker, R. Mdm2 mRNA expression is associated with survival in ovarian cancer. Int. J. Cancer, 74: 438-442, 1997.
32. Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., and Vogelstein, B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature, 358: 80-83, 1992.
33. Jiang, M., Shao, Z. M., Wu, J., Lu, J. S., Yu, L. M., Yuan, J. D., Han, Q. X., Shen, Z. Z., and Fontana, J. A. p21/waf1/cip1 and mdm-2 expression in breast carcinoma patients as related to prognosis. Int. J. Cancer, 74: 529-534, 1997.
34. Ng, I. O., Lam, K. Y., Ng, M., and Regezi, J. A. Expression of p21/waf1 in oral squamous cell carcinomas-correlation with p53 and mdm2 and cellular proliferation index. Oral Oncol., 35: 63-69, 1999.
35. Quesnel, B., Preudhomme, C., Fournier, J., Fenaux, P., and Peyrat, J. P. MDM2 gene amplification in human breast cancer. Eur. J. Cancer, 30A: 982-984, 1994.
36. Landers, J. E., Cassel, S. L., and George, D. L. Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein. Cancer Res., 57: 3562-3568, 1997.
37. Trotta, R., Vignudelli, T., Candini, O., Intine, R. V., Pecorari, L. Guerzoni, C., Santilli, G., Byrom, M. W., Goldoni, S., Ford, L. P., Caligiuri, M. A., Maraia, R. J., Perrotti, D., and Calabretta, B. BCR/ABL activates mdm2 mRNA translation via the La antigen. Cancer Cell, 3: 145-160, 2003.
38. Lundgren, K., Montes de Oca Luna, R., McNeill, Y. B., Emerick, E. P., Spencer, B., Barfield, C. R., Lozano, G., Rosenberg, M. P., and Finlay, C. A. Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53. Genes Dev., 11: 714-725, 1997.
39. Folberg-Blum, A., Sapir, A., Shilo, B., and Oren, M. Overexpression of mouse Mdm2 induces developmental phenotypes in Drosophila. Oncogene, 21: 2413-2417, 2002.
40. Ganguli, G., Abecassis, J., and Wasylyk, B. MDM2 induces hyperplasia and premalignant lesions when expressed in the basal layer of the epidermis [in Process Citation]. EMBO J., 19: 5135-5147, 2000.
41. Fridman, J. S., Hemando, E., Hemann, M. T., Stanchina, E. D., Cordon-Cardo, C., and Lowe, S. W. Tumor promotion by Mdm2 splice variants unable to bind p53. Cancer Res., 63: 5703-5706, 2003.
42. Jones, S. N., Hancock, A. R., Vogel, H., Donehower, L. A., and Bradley, A. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc. Natl. Acad. Sci. USA, 95: 15608-15612, 1998.
43. Sun, P., Dong, P., Dai, K., Hannon, G. J., and Beach, D. p53-independent role of MDM2 in TGF-β1 resistance. Science, 282: 2270-2272, 1998.
44. Blain, S. W. and Massague, J. Different sensitivity of the transforming growth factor-β1 cell cycle arrest pathway to c-myc and MDM2. J. Biol. Chem., 275: 32066-32070, 2000.
45. Iwakuma, T. and G. Lozano. MDM2, an Introduction. Mol. Cancer Res., 1: 993-1000.
46. Moll U. M. and Petrenko, O. The MDM2-p53 Interaction. Mol. Cancer Res., 1: 1001-1008.
47. Ganglui, G. and Wasylyk, B. p53-Independent Functions of MDM2. Mol. Cancer Res., 1: 1027-1035.
48. Xiao, Z. X., Chen, J., Levine, A. J., Modjtahedi, N., Xing, J., Sellers, W. R., and Livingston, D. M. Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature, 375: 694-698, 1995
49. Dobbelstein, M., Wienzek, S., Konig, C., and Roth, J. Inactivation of the p53-homologue p73 by the mdm2-oncoprotein. Oncogene, 18: 2101-2106, 1999.
50. Zeng, X., Chen, L., Jost, C. A., Maya, R., Keller, D., Wang, X., Kaelin, W. G., Jr., Oren, M., Chen, J., and Lu, H. MDM2 suppresses p73 function without promoting p73 degradation. Mol. Cell. Biol., 19: 3257-3266, 1999.
51. Pomerantz, J., Schreiber-Agus, N., Liegeois, N. J., Silverman, A., Alland, L., Chin, L., Potes, J., Chen, K., Orlow, I., Lee, H. W., Cordon-Cardo, C., and DePinho, R. A. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell, 92: 713-723, 1998.
52. Kamijo, T., Weber, J. D., Zambetti, G., Zindy, F., Roussel, M. F., and Sherr, C. J. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc. Natl. Acad. Sci. USA, 95: 8292-8297, 1998.
53. Zhang, Y., Xiong, Y., and Yarbrough, W. G. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell, 92: 725-734, 1998.
54. Momand, J., Zambetti, G. P., Olson, D. C., George, D., and Levine, A. J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell, 69: 1237-1245, 1992.
55. Brown, D. R., Deb, S., Munoz, R. M., Subler, M. A., and Deb, S. P. The tumor suppressor p53 and the oncoprotein simian virus 40 T antigen bind to overlapping domains on the MDM2 protein. Mol. Cell. Biol., 13: 6849-6857, 1993.
56. Chen, J., Marechal, V., and Levine, A. J. Mapping of the p53 and mdm-2 interaction domains. Mol. Cell. Biol., 13: 4107-4114, 1993.
57. Haines, D. S., Landers, J. E., Engle, L. J., and George, D. L. Physical and functional interaction between wild-type p53 and mdm2 proteins. Mol. Cell. Biol., 14: 1171-1178, 1994.
58. Leng, P., Brown, D. R., Shivakumar, C. V., Deb, S., and Deb, S. P. N-terminal 130 amino acids of MDM2 are sufficient to inhibit p53-mediated transcriptional activation. Oncogene, 10: 1275-1282, 1995.
59. Oliner, J. D., Pietenpol, J. A., Thiagalingam, S., Gyuris, J., Kinzler, K. W., and Vogelstein, B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature, 362: 857-860, 1993.
60. Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., and Pavletich, N. P. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science, 274: 948-953, 1996.
61. Chen, C. Y., Oliner, J. D., Zhan, Q., Fomace, A. J., Jr., Vogelstein, B., and Kastan, M. B. Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway. Proc. Natl. Acad. Sci. USA, 91: 2684-2688, 1994.
62. Chen, J., Wu, X., Lin, J., and Levine, A. J. Mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein. Mol. Cell. Biol., 16: 2445-2452, 1996.
63. Haupt, Y., Barak, Y., and Oren, M Cell type-specific inhibition of p53-mediated apoptosis by mdm2. EMBO J., 15: 1596-1606, 1996.
64. de Rozieres, S., Maya, R., Oren, M., and Lozano, G. The loss of mdm2 induces p53-mediated apoptosis. Oncogene, 19: 1691-1697, 2000.
65. Kondo, S., Bamett, G. H., Hara, H., Morimura, T., and Takeuchi, J. MDM2 protein confers the resistance of a human glioblastoma cell line to cisplatin-induced apoptosis. Oncogene, 10: 2001-2006, 1995.
66. Haupt, Y., Maya, R., Kazaz, A., and Oren, M. Mdm2 promotes the rapid degradation of p53. Nature, 387: 296-299, 1997.
67. Honda, R., Tanaka, H., and Yasuda, H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett., 420: 25-27, 1997.
68. Honda, R. and Yasuda, H. Association of p19 (ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. EMBO J., 18: 22-27, 1999.
69. Kubbutat, M. H., Jones, S. N., and Vousden, K. H. Regulation of p53 stability by Mdm2. Nature, 387: 299-303, 1997.
70. Argentini, M., Barboule, N., and Wasylyk, B. The contribution of the acidic domain of MDM2 to p53 and MDM2 stability. Oncogene, 20: 1267-1275, 2001.
71. Fang, S., Jensen, J. P., Ludwig, R. L., Vousden, K. H., and Weissman, A. M. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J. Biol. Chem., 275: 8945-8951, 2000.
72. Grossman, S. R., Deato, M. E., Brignone, C., Chan, H. M., Kung, A. L., Tagami, H., Nakatani, Y., and Livingston, D. M. Polyubiquitination of p53 by a ubiquitin ligase activity of p300. Science, 300: 342-344, 2003.
73. Honda, R. and Yasuda H. Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING finger domain of the ligase. Oncogene, 19: 1473-1476, 2000.
74. Zhu, Q., Yao, J., Wani, G., Wani, M. A., and Wani, A. A. Mdm2 mutant defective in binding p300 promotes ubiquitination but not degradation of p53. J. Biol. Chem., 276: 29695-29701, 2001.
75. Freedman, D. A. and Levine A. J. Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. Mol. Cell. Biol., 18: 7288-7293, 1998.
76. Zaika, A., Marchenko, N., and Moll, U. M. Cytoplasmically "Sequestered" wild type p53 protein is resistant to Mdm2-mediated degradation [In Process Citation]. J. Biol. Chem., 274: 27474-27480, 1999.
77. Maki, C. G. Oligomerization is required for p53 to be efficiently ubiquitinated by MDM2. J. Biol. Chem., 274: 16531-16535, 1999.
78. Juven-Gershon, T., Shifman, O., Unger, T., Elkeles, A., Haupt, Y., and Oren, M. The Mdm2 oncoprotein interacts with the cell fate regulator Numb. Mol. Cell. Biol., 18: 3974-3982, 1998.
79. Stott, F. J., Bates, S., James, M. C., McConnell, B. B., Starborg, M., Brookes, S., Palmero, I., Ryan, K., Hara, E., Vousden, K. H., and Peters, G. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J., 17: 5001-5014, 1998.
80. Martin, K., Trouche, D., Hagemeier, C., Sorensen, T. S., La Thangue, N. B., and Kouzarides, T. Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature, 375: 691-694, 1995.
81. Hsieh, J. K., Chan, F. S., O'Connor, D. J., Mittnacht, S., Zhong, S., and Lu, X. RB regulates the stability and the apoptotic function of p53 via MDM2. Mol. Cell, 3: 181-193, 1999.
82. Johnson-Pais, T., Degnin, C., and Thayer, M. J. pRB induces Sp1 activity by relieving inhibition mediated by MDM2. Proc. Natl. Acad. Sci. USA, 98: 2211-2216, 2001.
83. Brown, D. R., Thomas, C. A., and Deb, S. P. The human oncoprotein MDM2 arrests the cell cycle: elimination of its cell-cycle-inhibitory function induces tumorigenesis. EMBO J., 17: 2513-2525, 1998.
84. Dang, J., Kuo, M., Eischen, C. M., Stepanova, L., Sherr, C. J., and Roussel, M. F. The RING domain of Mdm2 can inhibit cell proliferation. Cancer Res., 62: 1222-1230, 2002.
85. Frum, R. A. and Deb, S. P. Flow cytometric analysis of MDM2-mediated growth arrest. In: p53 Protocols, vol. 234, pp. 257-267. Humana Press, New Jersey, 2003.
86. Hori, M., Shimazaki, J., Inagawa, S., Itabashi, M., and Hori, M. Overexpression of MDM2 oncoprotein correlates with possession of estrogen receptor α and lack of MDM2 mRNA splice variants in human breast cancer. Breast Cancer Res. Treat., 71: 77-83, 2002.
87. Mariatos, G., Gorgoulis, V. G., Kotsinas, A., Zacharatos, P., Kokotas, S., Yannoukakos, D., and Kittas, C. Absence of mutations in the functional domains of the human MDM2 oncogene in non-small cell lung carcinomas. Mutat. Res., 456: 59-63, 2000.
88. Silva, J., Silva, J. M., Dominguez, G., Garcia, J. M., Rodriguez, O., Garcia-Andrade, C., Cuevas, J., Provencio, M., España, P., and Bonilla, F. Absence ofpoint mutation at codon 17 of the Mdm2 gene (serine 17) in human primary tumors. Mutat. Res., 449: 41-45, 2000.
89. INK4b in undifferentiated mouse skin tumors. Cancer Res., 55: 5168-5172, 1995.
90. Quelle, D. E., Ashmun, R. E., Hannon, G. J., Rehberger, P. A., Trono, D., Richter, K. H., Walker, C., Beach, D., Sherr, C. J., and Serrano, M. Cloning and characterization of murine p16 INK4a and p15 INK4b genes. Oncogene, 11: 635-645, 1995.
91. Bae, I., Smith, M. L., and Fornaee, A. J., Jr. Induction of p53-, MDM2-, and WAF1/CIP1-like molecules in insect cells by DNA-damaging agents. Exp. Cell Res., 217: 541-545, 1995.
92. Hsing, A., Faller, D. V., and Vaziri, C. DNA-damaging aryl hydrocarbons induce Mdm2 expression via p53-independent post-transcriptional mechanism. J. Biol. Chem., 275: 26024-26031, 2000.
93. Perry, M. E., Piette, J.; Zawadzki, J. A., Harvey, D., and Levine, A. J. The mdm-2 gene is induced in response to UV light in a p53-dependent manner. Proc. Natl. Acad. Sci. USA, 90: 11623-11627, 1993.
94. Price, B. D. and Park S. J. DNA damage increases the levels of MDM2 messenger RNA in wtp53 human cells. Cancer Res., 54: 896-899, 1994.
95. Ries, S., Biederer, C., Woods, D., Shifman, O., Shirasawa, S., Sasazuki, T., McMahon, M., Oren, M., and McCormick, F. Opposing effects of Ras on p53: transcriptional activation of mdm2 and induction of p19ARF. Cell, 103: 321-330, 2000.
96. Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., and Lowe, S. W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell, 88: 593-602, 1997.
97. Ferbeyre, G., de Stanchina, E., Lin, A. W., Querido, E., McCurrach, M. E., Hannon, G. J., and Lowe, S. W. Oncogenic ras and p53 cooperate to induce cellular senescence. Mol. Cell. Biol., 22: 3497-3508, 2002.
98. Olsen, C. L., Gardie, B., Yaswen, P., and Stampfer, M. R. Raf-1-induced growth arrest in human mammary epithelial cells is p16-independent and is overcome in immortal cells during conversion. Oncogene, 21: 6328-6339, 2002.
99. O'Reilly, L. A., Huang, D. C. S., and Strasser, A. The cell death inhibitor Bcl-2 and its homologues influence control of cell cycle entry. EMBO J., 15: 6979-6990, 1996.
100. Zhu, L., van den Heuvel, S., Helin, K., Fattaey, A., Ewen, M., Livingston, D., Dyson, N., and Harlow, E. Inhibition of cell proliferation by p107, a relative of the retinoblastoma protein. Genes Dev., 7: 1111-1125, 1993.